• This is the first analysis of elbasvir/grazoprevir in Korean patients with hepatitis C virus (HCV) infection.

• All patients who completed 12 weeks of treatment achieved a sustained virologic response.

• The safety profile of elbasvir/grazoprevir was consistent with that from previous reports in Asian and Western patients.

• Elbasvir/grazoprevir administered for 12 weeks was well-tolerated and highly effective in Korean patients with HCV genotype 1b infection.

INTRODUCTION
============

In Korea, an estimated 231,000 individuals have chronic hepatitis C virus (HCV) infection, accounting for 0.5% of the total population \[[@b1-cmh-2019-0006]\]. Infection is more common among older people, with prevalence rates reaching 1.53% in those aged 60--69 years and 2.31% in those aged ≥70 years \[[@b2-cmh-2019-0006]\]. Approximately 45% of HCV-infected individuals have genotype (GT) 1b infection and a similar proportion have HCV GT2 infection \[[@b1-cmh-2019-0006]\]. HCV infection accounts for 15--20% of all chronic liver disease in Korea \[[@b3-cmh-2019-0006]\]. Direct-acting antiviral (DAA) agents for the treatment of HCV infection are available, and currently there are a total of six different all-oral regimens available for patients with GT1b infection, which vary in duration (12 weeks vs. 8 weeks) and requirement for coadministration of ribavirin according to variables such as treatment history, baseline viral load of HCV, and human immunodeficiency virus (HIV) coinfection \[[@b4-cmh-2019-0006]\].

Elbasvir (EBR, MK-8742)/grazoprevir (GZR, MK-5172) is a oncedaily, fixed-dose combination tablet for the treatment of patients with HCV GT1 or GT4 infection. The combination of EBR 50 mg/ GZR 100 mg has broad activity against most HCV GTs in vitro \[[@b5-cmh-2019-0006]-[@b7-cmh-2019-0006]\] and has consistently demonstrated high levels of efficacy and safety in a broad cross-section of people with HCV infection, including treatment-naive and treatment-experienced individuals and those with cirrhosis, HIV coinfection, or chronic kidney disease \[[@b8-cmh-2019-0006]-[@b13-cmh-2019-0006]\]. In Korea, EBR/GZR is recommended for individuals with HCV GT1 or GT4 infection, with a 12-week regimen recommended for all people with HCV GT1b infection, regardless of baseline demographics or disease characteristics \[[@b4-cmh-2019-0006]\]. Racial or ethnic background has been reported to impact the efficacy of DAA treatments for HCV infection \[[@b14-cmh-2019-0006]\], and EBR/GZR plasma levels are known to be higher in Asian compared with white individuals with HCV infection \[[@b15-cmh-2019-0006]\]. We have therefore assessed the clinical profile of EBR/ GZR in people from Korea, focusing on those with HCV GT1b infection, one of the most common HCV GTs in Korea. The aim of the present analysis was to evaluate the safety and efficacy of EBR/GZR administered for 12 weeks in Korean patients who were enrolled in four international phase 3 studies of EBR/GZR.

PATIENTS AND METHODS
====================

Study design
------------

This is a retrospective, *post hoc*, integrated analysis of data from patients with HCV GT1b infection enrolled at Korean study sites in the EBR/GZR clinical development program. All patients were enrolled in the C-EDGE Treatment-Naive \[[@b8-cmh-2019-0006]\] (NCT02105467/Protocol PN060), C-CORAL \[[@b13-cmh-2019-0006]\] (NCT02251990/PN067), C-SURFER11 (NCT02092350/ PN052), and C-EDGE Treatment-Experienced \[[@b9-cmh-2019-0006]\] (NCT02105701/ PN068) studies. All studies were conducted in accordance with the Declaration of Helsinki, current guidelines on Good Clinical Practices, and local ethical and legal requirements, and all patients provided written informed consent prior to any study-related procedures. The methodology and primary outcomes from these studies have been published previously \[[@b8-cmh-2019-0006],[@b9-cmh-2019-0006],[@b11-cmh-2019-0006],[@b13-cmh-2019-0006]\].

Patients
--------

Patients included in this analysis were aged \>18 years with chronic HCV GT1b infection and a baseline viral load \>10,000 IU/mL. Patients were treatment-naive or had previously failed interferonbased HCV therapy, and included those with HIV coinfection or Child-Pugh class A cirrhosis (defined as METAVIR F4 on liver biopsy within 24 months of enrollment; FibroScan^®^ (Echosens, Paris, France) \>12.5 kPa within 12 months of enrollment; or aspartate aminotransferase \[AST\]-to-platelet ratio \>2.0 and FibroTest^®^ \>0.75). Patients with decompensated liver disease (as indicated by a presence or history of ascites, esophageal or gastric variceal bleeding, hepatic encephalopathy or other signs of advanced liver disease), or evidence of hepatocellular carcinoma (HCC) were excluded from the original treatment studies. People who had previously received DAA therapy were also excluded from these studies.

Treatment
---------

All patients received EBR 50 mg/GZR 100 mg once daily, administered either as a coformulated fixed-dose combination tablet or as separate entities for 12 weeks. All patients were followed for 24 weeks after cessation of study therapy.

Outcomes
--------

The primary end point was HCV RNA \<15 IU/mL at 12 weeks after completion of therapy (sustained virologic response \[SVR\] at 12 weeks after completion of therapy, SVR12).

Procedures
----------

Plasma HCV RNA levels were measured using the cobas^®^ AmpliPrep/cobas^®^ TaqMan^®^ HCV test (version 2.0, Roche Molecular Diagnostics, Branchburg, NJ, USA) with a lower limit of quantitation of 15 IU/mL. Relapse was defined as HCV RNA \>15 IU/mL during follow-up after HCV RNA \<15 IU/mL at the end of treatment. Determination of HCV GT was conducted using the Versant HCV genotype assay (LiPA) 2.0 (Innogenetics, Ghent, Belgium) or the Abbott RealTime HCV Genotype II assay (Abbott Molecular Inc., Abbott Park, IL, USA). Resistance analyses were performed using population sequencing with a limit of minority variant detection \>20% of the viral population. Nonstructural protein 5A (NS5A) resistance-associated substitutions (RASs) were defined as any polymorphism at amino acid positions 28, 30, 31, and 93.

Analyses
--------

This is a retrospective analysis of data from four international phase 3 clinical trials. Efficacy analyses were performed on the full analysis set (FAS) population (which included all randomized patients who received at least one dose of drug) and the modified FAS (mFAS) population (which excluded patients who discontinued treatment for reasons unrelated to study drug). Safety analyses included all patients who received at least one dose of study medication. Resistance analyses were conducted in all patients with baseline sequencing and a treatment outcome of either SVR12 or virologic failure.

RESULTS
=======

Patients
--------

A total of 74 Korean patients originally enrolled in the C-EDGE Treatment-Naive \[[@b8-cmh-2019-0006]\] (n=36), C-CORAL \[[@b13-cmh-2019-0006]\] (n=31), C-SURFER \[[@b11-cmh-2019-0006]\] (n=4), and C-EDGE Treatment-Experienced \[[@b9-cmh-2019-0006]\] (n=3) studies were included in this analysis. Most (n=70, 94.6%) were treatment naive, and all had HCV GT1b infection ([Table 1](#t1-cmh-2019-0006){ref-type="table"}). Twenty-five (33.8%) had cirrhosis and 34 (45.9%) had a baseline viral load \>2,000,000 IU/mL. No patients in this analysis had HCV/HIV coinfection.

Virologic response
------------------

SVR12 was achieved by 73 of 74 (98.6%; 95% confidence interval \[CI\], 92.7--99.9%) Korean patients with HCV GT1b infection receiving EBR/GZR for 12 weeks in the FAS population ([Fig. 1](#f1-cmh-2019-0006){ref-type="fig"}). No patients had virologic failure and one patient discontinued from the study after withdrawing consent. This patient was excluded from the mFAS analysis, resulting in an SVR12 rate in the mFAS population of 100% (73/73).

SVR12 rates were uniformly high across all subgroups of Korean patients receiving EBR/GZR for 12 weeks ([Fig. 2](#f2-cmh-2019-0006){ref-type="fig"}). Notably, SVR12 was achieved by all patients with cirrhosis (25/25) and all those aged ≥65 years (16/16).

One patient, who withdrew consent, was excluded from the resistance analysis population owing to lack of virologic response data. Seventy-three patients were therefore assessed for the impact of baseline NS5A RASs at amino acid positions 28, 30, 31, or 93 on SVR12 rates. A total of 16 patients had RASs present at baseline (16/73, 22%), all of whom achieved SVR12 ([Fig. 3](#f3-cmh-2019-0006){ref-type="fig"}). The remaining 57 patients with no NS5A RASs at baseline also achieved SVR12.

Safety
------

Adverse events (AEs) were reported by 32/74 (43.2%) of Koreans receiving EBR/GZR for 12 weeks ([Table 2](#t2-cmh-2019-0006){ref-type="table"}). AEs reported in \>5% of Korean patients were fatigue (n=5, 6.8%), upper respiratory tract infection (n=4, 5.4%), headache (n=4, 5.4%), and nausea (n=4, 5.4%). Thirteen patients (17.6%) reported drug-related AEs and two serious AEs occurred, neither of which was considered drug-related (suicide; multiple fractures).

Two patients discontinued treatment. A 52-year-old man with cirrhosis had increased transaminase and bilirubin levels at treatment week 6 following ingestion of two bottles of the alcoholic beverage Soju the previous day. This patient met the protocolspecified discontinuation criteria of alanine aminotransferase (ALT) \>3× nadir and concomitant bilirubin increase \>2× upper limit of normal and per protocol was discontinued on day 57 of treatment \[[@b13-cmh-2019-0006]\]. The second patient who discontinued treatment had elevated ALT/AST levels at treatment week 10 (ALT, 668 U/L; AST, 459 U/L) that were considered drug-related and met the protocol criteria for discontinuation \[[@b8-cmh-2019-0006]\]. Both patients achieved SVR. Narratives for these patients have been reported previously \[[@b8-cmh-2019-0006],[@b13-cmh-2019-0006]\].

One death occurred in the study population. A 49-year-old woman without cirrhosis who was enrolled in the C-CORAL study committed suicide on day 57 of the study after withdrawing consent. This patient had no known history of depression or psychiatric illness and had reported suicidal ideation started 11 days prior to the event and refused further psychiatric consultation.

DISCUSSION
==========

Data from this analysis extend the clinical profile for EBR/GZR. High rates of SVR12 were achieved in Korean patients with HCV GT1b infection receiving EBR/GZR for 12 weeks. There were no virologic failures among the treated population (either on-treatment failure or relapse), and only one patient, who withdrew consent, failed to achieve SVR12. Thus, among patients in the mFAS analysis, which excluded the patient who withdrew consent, SVR12 was achieved by 100% (73/73) of patients. The safety profile of EBR/GZR in this study was consistent with previous reports in Asian and Western patients \[[@b16-cmh-2019-0006]\], in which there were no drug-related serious AEs and with two patients who discontinued treatment, one was due to a drug-related ALT/AST elevation.

The result of the present analysis compare favorably with previous reports of treatment options available for Korean patients with HCV GT1b infection. Two studies indicate that SVR rates of 88--90% are achievable in Korean individuals with HCV GT1b infection receiving daclatasvir plus asunaprevir for 24 weeks \[[@b17-cmh-2019-0006],[@b18-cmh-2019-0006]\]. In one of these studies, on-treatment virologic failures occurred in 7 of 76 treated patients, yielding an end-of-treatment response rate of 91% (69/76) \[[@b18-cmh-2019-0006]\]. In a single-arm phase 3b study, SVR12 was achieved by 99% (92/93) of Korean patients with HCV GT1 infection receiving sofosbuvir/ledipasvir for 12 weeks, the majority of whom had GT1b infection \[[@b19-cmh-2019-0006]\]. In this study, there were no on-treatment virologic failures and one relapsed patient who had the Y93 polymorphism present at baseline and time of failure.

A large integrated analysis of 1,070 patients with HCV GT1b infection has shown that EBR/GZR for 12 weeks is a safe and effective treatment option regardless of patient demographics or disease characteristics \[[@b20-cmh-2019-0006]\]. Overall, SVR12 was achieved by 97.2% (1,040/1,070) of patients and remained high in those with cirrhosis (188/189, 99.5%), HCV/HIV coinfection (51/54, 94.4%), and baseline viral load \>800,000 IU/mL (705/728, 96.8%). In this integrated population, 21.6% of patients had baseline RASs at amino acid positions 28, 30, 31, or 93. SVR12 was achieved by 99.6% (820/823) of those with no baseline RASs and 94.7% (215/227) of those with baseline RASs (including an SVR12 rate of 95.2% \[99/104\] in patients with Y93 polymorphisms) \[[@b20-cmh-2019-0006]\]. In the present analysis, all 16 Korean patients with baseline NS5A RASs achieved SVR12. Combined, these data are consistent with the approved use of EBR/GZR, in which testing for baseline RAS is not required prior to the treatment of people with GT1b infection \[[@b15-cmh-2019-0006]\].

The C-CORAL study examined the safety and efficacy of EBR/ GZR for 12 weeks in individuals with HCV GT1, GT4, or GT6 infection from Russia and countries across the Asia Pacific region \[[@b21-cmh-2019-0006]\]. Approximately 80% of patients enrolled in this study had HCV GT1b infection. Rates of SVR were high in patients from China (146/151, 97%), South Korea (48/50, 96%), Taiwan (83/85, 98%), Russia (117/118, 99%), and Australia (26/28, 93%) but were lower in Vietnam (27/33, 82%) and Thailand (12/21, 57%) owing primarily to the high rate of virologic failure among patients with HCV GT6 infection in these countries \[[@b21-cmh-2019-0006]\]. Analysis of the EBR/GZR clinical trial database has also revealed similarly high rates of SVR12 in patients recruited outside of Korea. Compared with SVR12 rates in the present analysis, 97.4% (378/388) of non-Korean Asian patients and 96.9% (589/608) of non-Asian patients in the database achieved SVR12. The high SVR rates described in Korean patients in the current analysis are therefore consistent with SVR rates reported in individuals with HCV GT1b infection from other countries receiving EBR/GZR for 12 weeks.

Although controversial, it has been hypothesized that initiation of DAA therapy for the treatment of HCV infection may result in de novo or recurrent HCC \[[@b22-cmh-2019-0006]\]. A recent long-term extension study enrolling patients from the EBR/GZR clinical development program (including but not restricted to the Korean patients described in this analysis) reported that 15 of 2,435 patients developed HCC following GZR-based therapy, resulting in an HCC incidence rate of 2.77 per 1,000 person-years (95% CI, 1.55--4.56) \[[@b23-cmh-2019-0006]\]. This rate is similar to or lower than previously reported rates, suggesting no correlation between GZR-containing regimens and HCC incidence \[[@b24-cmh-2019-0006]-[@b29-cmh-2019-0006]\].

This analysis had several limitations. Most patients in this study were treatment-naive and HCV mono-infected; caution when extrapolating these findings to other patients groups, such as those previously treated for HCV infection or those with HCV/HIV coinfection. Korean patients in this analysis were identified as individuals enrolled at Korean study sites: no additional measures were taken to confirm the nationality/race of patients. The comparison of SVR12 rates between Korean, Asian, and non-Asian patients was restricted to individuals with HCV GT1b infection who received EBR/GZR for 12 weeks; however, these populations may have differed with regard to other characteristics, such as the proportions with cirrhosis, HIV coinfection, high baseline viral load, or other comorbidities such as chronic kidney disease, inherited blood disorders, or active injection drug use.

In conclusion, EBR/GZR administered for 12 weeks was well-tolerated and highly effective in Korean patients with HCV GT1b infection. All patients who completed treatment achieved SVR, including all 16 with NS5A RASs at baseline. EBR/GZR represents an effective treatment option for Korean individuals with HCV GT1b infection.
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![SVR12 rates. Virologic outcome of patients treated with elbasvir (EBR)/grazoprevir (GZR). SVR12, sustained virologic response (SVR) at 12 weeks after completion of therapy; FAS, full analysis set; mFAS, modified FAS; AE, adverse event. ^\*^ Includes all patients who received at least one dose of study medication; ^†^ Excludes patients who discontinued treatment for reasons unrelated to study medication; ^‡^ One patient withdrew consent and did not achieve SVR12. This patient was excluded from the mFAS analysis.](cmh-2019-0006f1){#f1-cmh-2019-0006}

![SVR12 in select subgroups (FAS). Virologic outcome according to subgroups in full analysis set. SVR12, sustained virologic response at 12 weeks after completion of therapy; CI, confidence interval; FAS, full analysis set.](cmh-2019-0006f2){#f2-cmh-2019-0006}

![Prevalence and impact of baseline NS5A RASs (mFAS). Prevalence of RAS (A), Impact on virologic outcome (B). mFAS, modified full analysis set; NS5A, nonstructural protein 5A; RAS, resistance-associated substitution; SVR12, sustained virologic response (SVR) at 12 weeks after completion of therapy. Next-generation sequencing with an \~25% or \~15% cutoff at amino acid position 28, 30, 31, or 93. Resistance-analysis population includes patients with available sequence data and excludes one patient who withdrew consent and did not complete the study.](cmh-2019-0006f3){#f3-cmh-2019-0006}

###### 

Patients demographics

  Characteristic                                              Korean patients (n=74)
  ----------------------------------------------------------- ------------------------
  Sex                                                         
   Female                                                     42 (56.8)
   Male                                                       32 (43.2)
  Asian race                                                  74 (100)
  HCV GT1b                                                    74 (100)
  Age (years)                                                 55.0±11.0
  BMI (kg/m^2^)                                               24.2±3.3
  Treatment history                                           
   Treatment-naive                                            70 (94.6)
   Treatment-experienced                                      4 (5.4)
  Cirrhosis^[\*](#tfn1-cmh-2019-0006){ref-type="table-fn"}^   25 (33.8)
  HCV/HIV coinfection                                         0 (0)
  Baseline viral load                                         
   \>800,000 IU/mL                                            54 (73.0)
   \>2,000,000 IU/mL                                          34 (45.9)
  *IL28B* genotype                                            
   CC                                                         60 (81.1)
   Non-CC                                                     14 (18.9)

Values are presented as mean±standard deviation or n (%).

HCV, hepatitis C virus; GT, genotype; BMI, body mass index; HIV, human immunodeficiency virus.

In the original treatment studies, the presence of cirrhosis was defined as METAVIR F4 on liver biopsy within 24 months of enrollment, FibroScan^®^ \>12.5 kPa within 12 months of enrollment, or a combination of FibroTest^®^ score \>0.75 and aspartate aminotransferase:platelet ratio index \>2.

###### 

Safety and tolerability of elbasvir/grazoprevir (EBR/GZR) administered for 12 weeks

                                                                                       Korean patients (n=74)
  ------------------------------------------------------------------------------------ --------------------------------------------------------
  Any AEs                                                                              32 (43.2)
   Fatigue^[\*](#tfn2-cmh-2019-0006){ref-type="table-fn"}^                             5 (6.8)
   Upper respiratory tract infection^[\*](#tfn2-cmh-2019-0006){ref-type="table-fn"}^   4 (5.4)
   Headache^[\*](#tfn2-cmh-2019-0006){ref-type="table-fn"}^                            4 (5.4)
   Nausea^[\*](#tfn2-cmh-2019-0006){ref-type="table-fn"}^                              4 (5.4)
  Drug-related AEs                                                                     13 (17.6)
  Serious AEs                                                                          2 (2.7)
  Drug-related serious AEs                                                             0 (0)
  Discontinuation owing to AEs                                                         2^[†](#tfn3-cmh-2019-0006){ref-type="table-fn"}^ (2.7)
  Death                                                                                1^[‡](#tfn4-cmh-2019-0006){ref-type="table-fn"}^ (1.4)

Values are presented as n (%).

AEs, adverse events.

AEs listed occurred at a frequency ≥5%.

Two patients discontinued treatment owing to AEs: one had increased transaminase and bilirubin levels following ingestion of two bottles of Soju; the second had elevated alanine aminotransferase/aspartate aminotransferase (ALT/AST) and eosinophil levels at treatment week 10 that met the protocol criteria for discontinuation. Both patients achieved sustained virologic response.

One patient withdrew consent and then committed suicide.

[^1]: These data were presented at The Liver Week 2018; June 14--16, 2018; Incheon, Republic of Korea.
